Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMYMP) Shares Outstanding (2016 - 2025)

Bristol Myers Squibb (BMYMP) has disclosed Shares Outstanding for 17 consecutive years, with $2.9 billion as the latest value for Q4 2025.

  • Quarterly Shares Outstanding changed 0.0% to $2.9 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.9 billion through Dec 2025, changed 0.0% year-over-year, with the annual reading at $2.9 billion for FY2025, 0.0% changed from the prior year.
  • Shares Outstanding for Q4 2025 was $2.9 billion at Bristol Myers Squibb, down from $2.9 billion in the prior quarter.
  • The five-year high for Shares Outstanding was $2.9 billion in Q1 2021, with the low at $2.9 billion in Q4 2024.
  • Average Shares Outstanding over 5 years is $2.9 billion, with a median of $2.9 billion recorded in 2021.
  • The sharpest move saw Shares Outstanding crashed 75.95% in 2021, then skyrocketed 315.79% in 2022.
  • Over 5 years, Shares Outstanding stood at $2.9 billion in 2021, then changed by 0.0% to $2.9 billion in 2022, then changed by 0.0% to $2.9 billion in 2023, then dropped by 0.79% to $2.9 billion in 2024, then changed by 0.0% to $2.9 billion in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $2.9 billion, $2.9 billion, and $2.9 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.